Winners of the second annual Lyfebulb-Helsinn Innovation Summit & Awards in Oncology announced
Lyfebulb, a patient-empowerment platform that connects patients with industry to support user-driven innovation, and Helsinn, a Swiss pharmaceutical group focused on building quality cancer care, today announced that Mihir Shah of UE LifeSciences and Pierluigi Paracchi of Genenta Science were chosen as winners of the second Lyfebulb-Helsinn Innovation Summit and Awards in Oncology. Mihir received the Lyfebulb-Helsinn Innovation Award, and Pierluigi received The Squinto-LePera award, which was presented by Dr. Stephen Squinto and Denise LePera. The awards recognize outstanding innovations by Patient Entrepreneurs which advance solutions in the prevention, management or care of cancer, and have the potential to be commercialized.
Oncoceutics licenses rights for its anti-cancer compound to Ohara
US based Oncoceutics, Inc. has announced the outlicense of the rights to the company’s lead compound, ONC201, for Japan to Ohara Pharmaceutical Co., Ltd. In addition, Ohara will receive a right of first refusal on the license of ONC201 for additional areas, including most of Asia and West Africa, and a right of first refusal for the company’s next generation compound, ONC206, in these territories.
Temple medical school awarded grant for brain injury research
Researchers from the Lewis Katz School of Medicine and other medical professionals in Philadelphia institutions received a $700,000 grant to research traumatic brain injuries.
Part of the grant from The Science Center, a nonprofit that supports technological advancement, was awarded to Servio Ramirez, a Temple University pathology and laboratory medicine professor, and his team of researchers from the Katz School of Medicine, who are developing ways to detect and diagnose TBI through the bloodstream. The Children’s Hospital of Philadelphia, University of Delaware and the University of Pennsylvania will also receive part of the combined award.
Cambridge Innovation Center (CIC) announces the promotion of Sally J. Guzik to Director of CIC Philadelphia, the company’s newest campus, located at 3675 Market Street in uCity Square. As Director, Guzik will be responsible for supporting and expanding CIC Philadelphia’s entrepreneurial ecosystem and amplifying the good work taking place within it by recruiting more innovative, civically-minded organizations to CIC and the region.
What do Kendrick Lamar, King Tut and Thermo Fisher have in common?
Earlier this week, 7th graders from the Science and Leadership Academy Middle School (SLAMS) in West Philadelphia, experienced a “home-coming” of sorts when they reunited with the Science Center’s FirstHand program; but this time in its new home at 3675 Market. Last year, the students participated in Polymer Play at FirstHand’s previous 3624 Market location.
Spark Therapeutics’ $4.8B deal confirmed as biggest-ever VC-backed exit in Philly
The eye-popping $4.8 billion sticker price on Spark Therapeutics’ acquisition deal with Roche announced on Monday is shaping up to be the largest exit ever within city limits for a venture-backed company, according to data from financial data provider PitchBook and the Philadelphia Alliance for Capital and Technologies (PACT).
Etsy for gaming tools? Meet the Philly startup that wants to help you ace that video game
Once upon a time, video games were pretty basic. Consider Pac-Man, the chomping mouth that devoured small dots while moving through a maze.
Now, games are so complex that players need Excel spreadsheets, calculators, and troop-deployment schedules to wage virtual wars, capture castles, and build strategic alliances with players in other states and countries. Having an engineering degree helps.